In just a few years, peptides have grown from fringe drugs popular with fitness buffs and ‘looksmaxxers’ to a billion-dollar black market. Now, with the prospect of regulation on the horizon, healthcare players and investors are racing to cash in.
On today’s Big Take podcast, Bloomberg reporters Amanda Mull and Madison Muller join host Sarah Holder to break down the peptide boom, the safety concerns surrounding it and how a friendly Trump administration could bring it into the mainstream.
Read more: Peptides Fuel a Multibillion-Dollar Startup Race
Hosted by Sarah Holder; Produced by Laura Newcombe, Victor Swezey; Reported by Amanda Mull, Madison Muller; Edited by Julia Weaver, Aaron Edwards.
Fact-checking by Julia Press; Engineering by Alex Sugiura.
Senior Producer: Naomi Shavin; Deputy Executive Producer: Julia Weaver. Executive Producer: Nicole Beemsterboer.

‘Claude, How Should I Vote in 2026?’
17:10

Asia’s AI Stock Frenzy Is a Warning Sign for Global Markets
17:29

Special Report: US Supreme Court Upholds Birthright Citizenship
01:28